Small-molecule tyrosine kinase inhibitors as radiosensitizers

Seminars in Radiation Oncology

Volumn 12, Issue 3 SUPPL. 2, 2002, Pages 33-36

  Lawrence, Theodore S ^a   Nyati, Mukesh K ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIBODY; CANERTINIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GROWTH FACTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; CLINICAL TRIAL; DIARRHEA; DRUG BINDING; DRUG BLOOD LEVEL; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; RASH; REVIEW;

EID: 0036638329     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1053/srao.2002.34867     Document Type: Review

References (12)

1. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: Progression from reversible to irreversible inhibitors
2. Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer
3. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas
4. Anticancer therapy targeting the erbB family of receptor tyrosine kinases
5. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB 2, by a new class of tyrosine kinase inhibitor
6. Studies leading to the identification of ZD1839 (IRESSA): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer
7. Small molecule EGF receptor tyrosine kinase inhibitor ZD1839 (IRESSA) inhibits HER2/neu (erb-2) overexpressing breast tumor cells
8. Final results of the dose escalation phase of a phase I pharmacokinetics (PK), pharmacodynamic (PD) and biological activity study of ZD1839: NCIC CTG Ind.122
9. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
10. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck
11. Phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC)
12. Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor